UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 17, 2024
Entero Therapeutics, Inc. | ||
(Exact name of registrant as specified in its charter) |
Delaware | 001-37853 | 46-4993860 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
777 Yamato Road, Suite 502 Boca Raton, Florida |
33431 | |
(Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code: (561) 589-7020
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) |
Name of each exchange on which |
||
Common Stock, par value $0.0001 per share | ENTO | Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On July 17, 2024, the Board of Directors (the “Board”) of Entero Therapeutics, Inc. (the “Company”), received a letter (the “Letter”) from Dr. Jack Syage, the Company’s Chief Scientific Officer, President and member of the Board, whereby he tendered his resignation from the role of Chief Scientific Officer of the Company, effective immediately.
Dr. Syage will continue in his roles with the Company as its President and member of the Board. Dr. Syage resigned as Chief Scientific Officer in connection with certain cost reduction measures taken by the Company and not due to a disagreement with the Company’s operations, policies or practices.
In the Letter, Dr. Syage agreed to reduce his annual base salary to $66,560, effective July 1, 2024. Other than this change in annual base salary, Dr. Syage’s compensation and employment terms, as set forth in his offer letter dated March 13, 2024, will not change as a result of the resignation from the officer position described above.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Entero Therapeutics, Inc. | ||
July 23, 2024 | By: | /s/ James Sapirstein |
Name: | James Sapirstein | |
Title: | Chief Executive Officer |